Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy.

Centre Hospitalier Universitaire, Amiens, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Amiens
Treatments:ChemotherapyHospital:Centre Hospitalier Universitaire
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 2 study involved 60 T cell lymphoma patients whose cancer had progressed after prior chemotherapy. The median patient age was 66 years and 38 patients were male.

Treatment:
Patients were treated with the chemotherapy agent bendamustine.

Toxicities:
There were 4 reported deaths due to infection. Grade 3-4 neutropenia, inflammation of the lining of the GI tract (mucositis), and thrombocytopenia were also reported.

Results:
The median progression-free survival was 3.6 months and the median overall survival was 6.2 months.

Support:
This study was supported by Mundipharma, Roche, and Chugai, which are pharmaceutical companies.

Correspondence: Dr. Gandhi Damaj; email: [email protected]



Back